Neptune Krill Oil Tests Below Strictest Detection Limits for PCB and Recognized as a Target of Excellence by Industry Peers and
March 04 2010 - 12:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) assures its customers that it has
been unaffected by the recent polychlorinated biphenyl ("PCB")
contamination observed in marine oils and confirms Neptune Krill
Oil's ("NKO®") safety and quality. In addition, NKO® is recognized
by industry peers as the golden standard for krill oils.
"Neptune provides high quality in purity, composition and
benefits with its products. We regularly have the purity of NKO®
rigorously tested at independent accredited laboratories for all
potential contaminants including PCBs, dioxins, pesticides and
heavy metals, among others. NKO® complies with strict standards,
which justifies its regulatory approvals in the U.S., Canada, the
European Union and Australia. Unlike some other marine oil
manufacturers, Neptune is not concerned nor is it affected by the
recent observation of fish oil PCB contamination," said Dr. Tina
Sampalis, CSO of Neptune.
Also, according to the news published on Nutra-Ingredients on
March 2nd, 2010 1, Valensa International
("Valensa") is trying to improve Aker BioMarine's ("Aker") Superba
Krill Oil by adding astaxanthin, attempting to reach NKO® levels of
naturally occurring astaxanthin.
"This move apparently makes perfect sense, but it doesn't," said
Mr. Henri Harland, President and CEO of Neptune. "Valensa openly
acknowledges a weakness of Aker's Superba Krill Oil, which contains
substantially less antioxidants than NKO®. Matching the
quantity of astaxanthin in their product to NKO® levels does not
necessarily mean matching the benefits. In fact, their decision to
add Valansa`s Zanthin astaxanthin to reach NKO®'s naturally
occurring astaxanthin levels confirms the position of NKO® as the
golden standard in the krill oil industry," he stated.
"Moreover Neptune disputes Valensa's
statement about having the most stable krill oil in the market
with only 2 years stability while Neptune already guarantees a 3
years real time stability for NKO®," he added.
"We are concerned about the consumers who will believe that an
equal astaxanthin level actually means equal benefits," said Dr.
Tina Sampalis. "This is not necessarily the case. It is fundamental
to consider that the astaxanthin in NKO® is esterified on omega-3
fatty acids, most prominently EPA, one of the two bioactive
omega-3s. This is not the case with astaxanthin derived from plant
sources such as algae, such as Zanthin, the astaxanthin added to
Aker's Superba Krill Oil. Esterified astaxanthin improves the
antioxidant activity in the body, which is essential in order to
adequately prevent systemic oxidation, a critical risk factor for
inflammatory and cardiovascular disease," she concluded.
About Neptune
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease.
The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory
approval for label health claims. Neptune is continuously expanding
its intellectual property portfolio as well as clinical studies and
regulatory approvals. Neptune's products are marketed and
distributed in over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner has been initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
1 :
http://www.nutraingredients-usa.com/Industry/Valensa-adds-astaxanthin-to-krill-oil-in-new-ingredient
NASDAQ does not accept responsibility for the adequacy or
accuracy of this press release. Neither TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Statements in this press release that are not statements of
historical or current fact, including statements relating to the
Company's expectation regarding the future performance and
marketability of its products, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates,"should," "will," or "plans" to
be uncertain and forward-looking. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company's
reports filed with the Securities and Exchange Commission and the
Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, C.A., Vice-president, Administration and Finance
450-687-2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
![](http://www.globenewswire.com/newsroom/ti?nf=MTYwIzE4NTgzOSMxMTg0OA==)
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024